The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Moderate to strong cytoplasmic immunoreactivity was observed in most prostate cancers and colorectal cancers and in rare cases of lung-, thyroid- and renal cancer. Remaining tumors were in general negative.
Malignant carcinoids, prostate, colorectal and liver cancers as well as several cases of malignant melanomas, thyroid, gastric and renal cancers exhibited moderate to strong positivity. Remaining malignancies showed distinct staining in fractions of cases but were in general negative.
Colorectal, prostate and liver cancers displayed strong cytoplasmic immunoreactivity in several cases.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
